AbbVie Expects $12.7 Billion in Neuroscience Sales This Year

AbbVie (ABBV) management projects $12.7 billion in sales from its neuroscience division this year. The company is focusing on expanding its portfolio in this area, which is becoming an increasingly significant part of its operations. This projection reflects AbbVie's strategy to leverage its existing resources and expertise to capitalize on growth in the neuroscience market. For investors, the anticipated earnings could signal positive momentum for AbbVie's stock performance as it strengthens its market position.